Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Genz-10850 is a synthetic small molecule compound characterized by a complex molecular structure that includes a piperazine ring, fluorene moiety, and indole ring[2][3]. It belongs to the class of organic compounds known as fluorenes[1]. Genz-10850 acts as an inhibitor of enoyl-[acyl-carrier-protein] reductase (NADH), which is part of the mycobacterial type II fatty acid synthase (FAS-II) system. This enzyme is essential for the synthesis of mycolic acids in Mycobacterium tuberculosis, making it a potential target for antitubercular drug development[4][6]. The compound has been investigated primarily in preclinical studies for its antimycobacterial activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Genz-10850.